BMO Capital Maintains Outperform on Pfizer, Lowers Price Target to $44
Portfolio Pulse from richadhand@benzinga.com
BMO Capital analyst Evan David Seigerman has maintained an 'Outperform' rating on Pfizer (NYSE:PFE) but lowered the price target from $45 to $44.
August 04, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer's price target has been lowered from $45 to $44 by BMO Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by BMO Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100